{
  "id": 20279104,
  "title": "AstraZeneca Secures Dual Rare Disease and Bladder Cancer Approvals Across US, Europe",
  "url": "https://urgent.news/2026/11/16/astrazeneca-secures-dual-rare-disease-and-bladder-cancer-approvals",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-16T12:52:34.000Z",
  "source": {
    "name": "Benzinga",
    "slug": "benzinga",
    "url": "https://www.benzinga.com/news/fda/26/11/63285561/astrazeneca-secures-dual-rare-disease-and-bladder-cancer-approvals-across-us-europe"
  },
  "original_language": "en",
  "account": null,
  "summary": "Regulators in the U.S. and European Union handed AstraZeneca Plc (NYSE:AZN) major regulatory wins across rare neuromuscular disease and oncology . The agencies cleared Klygefa for generalized myasthenia gravis and approved the Imfinzi combination regimen for muscle-invasive bladder cancer. FDA And EU Clear Klygefa For Generalized Myasthenia Gravis Monday, the U.S. Food and Drug Administration and…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}